- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01868880
Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing
Effect of Heart Rate Control Using Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Ventricular Pacing in Heart Failure Patients With an Implanted Cardioverter Defibrillator.
The aim of this prospective, randomized and controlled trial is to evaluate the use of the ivabradine in combination to a low-dose of beta-blocker (bisoprolol) versus up-titration of beta-blocker (bisoprolol) to obtain heart rate (HR) control with reduction in RV pacing in single-chamber or dual chambers ICD recipients HF patients with moderate to severe left ventricular dysfunction (FE ≤ 40%) and an heart rate ≥ 70 bpm in sinus rhythm over a 12-months follow up.
Besides the investigators want to assess if the combination of ivabradine to a low-dose of beta-blocker (bisoprolol) versus up-titration of beta-blocker (bisoprolol) may determine a lower degree of left ventricular dysfunction progression, the reduction of ventricular arrhythmias burden and ICD appropriate therapy occurrence and the improvement of quality of life in ICD heart failure patients.
Study Overview
Status
Intervention / Treatment
Detailed Description
Background
High heart rate (HR) represent per se a risk factor for cardiovascular mortality and heart failure (HF) progression, despite optimal HF therapy. Beta-blockers remain the therapy of choice in all patients with systolic HF, but they may worsen atrioventricular (AV) conduction and increase right ventricular (RV) pacing percentage. Several studies have demonstrated detrimental effects of RV pacing on cardiac function. Percent RV pacing > 40-50% is an independent predictor of death and hospitalization for HF in implantable cardioverter-defibrillator(ICD) patients, particularly in those with preexistent left ventricular dysfunction.1,2 Cumulative RV pacing > 2% and ejection fraction (EF) < 40% are independent predictors for Ventricular Tachycardia(VT)/Ventricular Fibrillation (VF) occurrence in ICD patients.3 Therefore reduction of cumulative RV pacing as far as possible should be achieved in ICD patients. Ivabradine is a specific inhibitor of the If current of the sinus node, that induces a selective and dose dependent HR reduction; it is a pure HR lowering agent without effects on AV conduction or contractility.4 In HF patients implanted with an ICD ivabradine could act as an heart rate control drug in combination with a beta-blocker without increase right ventricular (RV) pacing percentage and may be an option to reduce left-ventricular dysfunction progression and ventricular arrhythmias burden and appropriate ICD therapy.
Aim
The aim of this prospective, randomized and controlled trial is to evaluate the use of the ivabradine in combination to a low-dose of beta-blocker (bisoprolol) versus up-titration of beta-blocker (bisoprolol) to obtain heart rate (HR) control with reduction in RV pacing in single-chamber or dual chambers ICD recipients HF patients with moderate to severe left ventricular dysfunction (FE ≤ 40%) and an heart rate ≥70 bpm in sinus rhythm over a 12-months follow up.
Besides we want to assess if the combination of ivabradine to a low-dose of beta-blocker (bisoprolol) versus titration of beta-blocker (bisoprolol) may determine a lower degree of left ventricular dysfunction progression, the reduction of ventricular arrhythmias burden and ICD appropriate therapy occurrence and the improvement of quality of life in ICD heart failure patients.
Endpoints of the study
Primary endpoints:
Right ventricular pacing percentage increase > 50% or Cardiovascular death or Heart failure decompensation or Crossover due to worsening heart failure.
Secondary endpoints:
Ejection fraction decrease < 5% and Left Ventricular End-Systolic Volume decrease <15%.
Ventricular arrhythmias and ICD appropriate therapy reduction. Heart rate variability improvement NYHA Classification improvement Minnesota Living With Heart Failure Questionnaire (MLHFQ) total score reduction.
Right ventricular pacing percentage. Composite endpoint: cardiovascular death and hospitalization due to worsening heart failure.
Crossover rate due to worsening heart failure
Study protocol:
Baseline assessment:
Clinical visit: demographic data, risk factors for cardiovascular disease, primary cause of heart failure, NYHA class, comorbidities, echocardiographic parameters, drug therapy, cardiovascular hospitalizations in the last year.
Rest ECG (for assessment of rest heart rate, presence of sinus rhythm or device-induced rhythm, QRS duration); Blood pressure measurement; Electronic device control (for assessment of right ventricular stimulation percentage; electrical parameters and arrhythmias diagnostic data); Echocardiogram (for assessment of left ventricular end-diastolic and end-systolic volumes, left ventricular ejection fraction); MLHFQ
Assignment of consecutive patients to treatment with ivabradine plus beta-blocker(bisoprolol) or beta-blocker (bisoprolol) titration. Mean Heart Rate Target is 55-70 bpm for both groups.
Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
Patients are controlled in office follow-up visits after 3, 6 and 12 months, in addition to a Remote Monitoring program for clinical data and trend reviewing at least every 15 days or as soon as possible whenever a Remote Monitoring alert notification is received. Besides every 15 days patients will receive a telephone contact in order to evaluate their clinical state and to uptitrate the beta blocker therapy based on mean heart rate detected trough remote control of the ICD.
Three months in-office follow-up:
Clinical visit: symptoms, NYHA class, drug therapy, cardiovascular hospitalizations in the last three months.
Rest ECG (for assessment of rest heart rate, presence of sinus rhythm or device-induced rhythm, QRS duration); Blood pressure measurement; Echocardiogram (for assessment of left ventricular end-diastolic and end-systolic volumes, left ventricular ejection fraction); Electronic device control (for assessment of right ventricular stimulation percentage; electrical parameters and arrhythmias diagnostic data) .
Six months in office follow-up:
Clinical visit: NYHA class, comorbidities, echocardiographic parameters, drug therapy, cardiovascular hospitalizations in the last three months.
Rest ECG (for assessment of rest heart rate, presence of sinus rhythm or device-induced rhythm, QRS duration); Echocardiogram (for assessment of left ventricular end-diastolic and end-systolic volumes, left ventricular ejection fraction); Electronic device control (for assessment of right ventricular stimulation percentage; electrical parameters and arrhythmias diagnostic data).
MLHFQ
One year in office follow-up:
Clinical visit: NYHA class, comorbidities, echocardiographic parameters, drug therapy, cardiovascular hospitalizations in the last three months.
Rest ECG (for assessment of rest heart rate, presence of sinus rhythm or device-induced rhythm, QRS duration); Electronic device control (for assessment of right ventricular stimulation percentage; electrical parameters and arrhythmias diagnostic data).
Echocardiogram (for assessment of left ventricular end-diastolic and end-systolic volumes, left ventricular ejection fraction); MLHFQ
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Rome, Italy, 00169
- Polinico Casilino
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Age ≥ 18 years.
Patients with stable chronic heart failure implanted with mono-cameral or bicameral ICD with a home monitoring remote control.
Moderate to severe left ventricular dysfunction (FE ≤ 40%).
Any cause of heart failure was allowed apart congenital heart disease.
Bicameral ICD programmed in DDD or AAI/DDD with AV interval < 300 msec.
Rest ECG heart rate ≥70 bpm;
Sinus rhythm.
In therapy with low-dose of beta-blocker (bisoprolol 1,25-2,5 mg) and with the maximum dose tolerated of angiotensin-converting enzyme inhibitor or blockade of angiotensin II receptor, mineralocorticoid antagonist, antiplatelet and lipid-lowering therapy, unless contraindicated.
Exclusion Criteria:
Inability of providing informed consent;
Age < 18 years.
State of pregnancy or lactation.
Recent (<2 months) myocardial infarction;
Contraindications to beta-blockers and ivabradine;
Rest ECG heart rate < 70 bpm;
No sinus rhythm.
Administration of non-dihydropyridinic calcium channels antagonists, digitalis, class I antiarrhythmic drugs, strong inhibitors of cytochrome P450 3A4 at the time of enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ivabradine plus beta-blocker(bisoprolol)
Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg).
After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
|
Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg).
After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
|
Active Comparator: beta-blocker (bisoprolol) titration
Beta blocker Bisoprolol will be titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
|
Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Right ventricular pacing percentage increase > 50% or cardiovascular death or Heart failure decompensation or Crossover due to worsening heart failure.
Time Frame: 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of episodes of non-sustained and sustained ventricular tachycardia and ventricular fibrillation
Time Frame: 12 months
|
12 months
|
Number of ICD shock-delivery for ventricular fibrillation and sustained ventricular tachycardia
Time Frame: 12 months
|
12 months
|
Ejection fraction decrease < 5% from baseline value
Time Frame: 12 months
|
12 months
|
Left Ventricular End-Systolic Volume decrease <15% from baseline value
Time Frame: 12 months
|
12 months
|
Heart rate variability increase (> 10%) from baseline value
Time Frame: 12 months
|
12 months
|
reduction of at least one NYHA Class from baseline value
Time Frame: 12 months
|
12 months
|
Change in Minnesota Living Heart Failure Questionnaire scores (>5) from the baseline score.
Time Frame: 12 months
|
12 months
|
Right ventricular pacing percentage reduction (> 10%) from baseline value
Time Frame: 12 months
|
12 months
|
Composite endpoint: number of cardiovascular death and hospitalization due to worsening heart failure.
Time Frame: 12 months
|
12 months
|
Crossover rate due to worsening heart failure
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Sharma AD, Rizo-Patron C, Hallstrom AP, O'Neill GP, Rothbart S, Martins JB, Roelke M, Steinberg JS, Greene HL; DAVID Investigators. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm. 2005 Aug;2(8):830-4. doi: 10.1016/j.hrthm.2005.05.015.
- Smit MD, Van Dessel PF, Nieuwland W, Wiesfeld AC, Tan ES, Anthonio RL, Van Erven L, Van Veldhuisen DJ, Van Gelder IC. Right ventricular pacing and the risk of heart failure in implantable cardioverter-defibrillator patients. Heart Rhythm. 2006 Dec;3(12):1397-403. doi: 10.1016/j.hrthm.2006.08.006. Epub 2006 Aug 10.
- Borer JS, Le Heuzey JY. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther. 2008 Sep-Oct;15(5):461-73. doi: 10.1097/MJT.0b013e3181758855.
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Failure
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Bisoprolol
- Adrenergic beta-Antagonists
Other Study ID Numbers
- calo03 (Other Identifier: Policlinico Casilino)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Rate Control in ICD Patients With Heart Failure
-
University Hospital, SaarlandFriede Springer Herz StiftungCompletedHeart Failure Patients Before and After ICD ImplantationGermany
-
National Taiwan University HospitalEnrolling by invitationto Assess the Corresponding PEEP Values in NIV With CPAP Under Different Airflow Rates During HFOT in Heart Failure PatientsTaiwan
-
Chelsea and Westminster NHS Foundation TrustCW Plus CharityCompletedCardiovascular Diseases | Heart Rate Control | Musical Heart Rhythm RegulationUnited Kingdom
-
University of LeicesterNational Institute for Health Research, United KingdomCompletedPatients With Heart Failure and Preserved Ejection Fraction - HFpEF | Patients With Heart Failure With Reduced Ejection Fraction - HFrEF | Healthy Controls Group - Age and Sex-matched
-
CMC Ambroise ParéWithdrawnCompare Two Programming Modalities for CRT Devices in Heart Failure Patients With an Indication for Cardiac Resynchronization TherapyMonaco, France
-
shaimaa MostafaCompletedAssessment of the RV Function in Patients With Heart Faliure
-
Assiut UniversityNot yet recruitingAssess the Relation Between Glycemic Gab and Adverse Clinical Outcomes in Diabetic Patients Who Hospitalized With Heart Failure
-
Gérond'ifNot yet recruitingPatients Hospitalized in Geriatrics for Heart Failure | Patients Aged 75 and Over
-
Nanjing Medical UniversityCompletedHeart Failure | Atrial Fibrillation | Rate Control | Catheter AblationChina
-
Catharina Ziekenhuis EindhovenCompletedIntrathoracic Blood Volume in Heart Failure PatientsNetherlands
Clinical Trials on Ivabradine plus beta-blocker (bisoprolol)
-
Ain Shams UniversityCompletedCardiovascular DiseasesEgypt
-
Policlinico Casilino ASL RMBCompletedInappropriate Sinus TachycardiaItaly
-
Hannover Medical SchoolCharite University, Berlin, GermanyUnknownPostural Orthostatic Tachycardia SyndromeGermany
-
Merck KGaA, Darmstadt, GermanyMerck Gesellschaft mbH, AustriaCompleted
-
Ain Shams UniversitySadat City UniversityUnknownDecompensated Heart Failure | Heart Failure With Reduced Ejection FractionEgypt
-
Oman Medical Speciality BoardNot yet recruitingAtrial Fibrillation With Rapid Ventricular Response | Atrial Flutter With Rapid Ventricular ResponseOman
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...CompletedMitral StenosisBangladesh
-
Damanhour UniversityCompleted
-
Merck KGaA, Darmstadt, GermanyMerck Ltd.Completed
-
Université de SherbrookeLaval UniversityCompleted